Fluidigm Expands Accessibility of Mass Cytometry and Imaging Mass Cytometry Technology with New Therapeutic Insights Services
Custom Projects and Consultation from
Providing Instrument Access Prior to Purchase Decision and Much‑Needed Capacity for Customers Affected by COVID-19 Related Laboratory Closures
New Collaboration via Therapeutic Insights Services Provides Visikol Customers Access to Rich Data and Powerful Analysis Tools from Imaging Mass Cytometry
The menu of Therapeutic Insights offerings includes consultation from experimental panel design to data analysis, custom antibody sourcing, conjugation and verification, staining for IMC with standard or custom panels, mass cytometry or IMC data acquisition and powerful data analysis tools.
“By broadening the access to mass cytometry and IMC, Therapeutic Insights Services provides researchers with new capabilities in interrogating the tissue microenvironment, helping them answer important questions in developmental biology, disease progression and response to therapy,” said
“Customers affected by COVID-19 related closures of local research facilities, as well as those who wish to use mass cytometry and IMC before making an instrument purchase decision, will now have access to this important technology,” said Linthwaite. “In addition,
“We are excited for the opportunity to share this platform and its considerable capabilities with many more researchers in the global scientific community.”
Concurrently with the launch of Therapeutic Insights Services,
"We teamed up with
“Our clients will now have the ability to acquire rich IMC data from their samples, with customizable service options including panel design, data acquisition, analysis and a range of others that add significant value. Most importantly, our clients will benefit from an unprecedented array of imaging-based tissue endpoints that lead to more meaningful insights.”
Learn more about Therapeutic Insights Services: https://www.fluidigm.com/singlearticles/therapeutic-insights-services
We use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Visikol is a CRO focused on advanced drug discovery that is leading the fields of bio-imaging, bioinformatics and image analysis. We conduct end-to-end drug discovery services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, digital pathology and custom drug discovery projects. Visikol offers a portfolio of drug discovery services ranging from 2D and 3D cell culture model and assay development to in vitro screening, animal tissue histology and automated image processing. The focus of these services is to transform tissues into images and ultimately into quantitative data sets that can be mined for actionable insights that help our Clients make more informed decisions during the drug discovery process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. For more information about Visikol or its services, please visit our website at visikol.com.
Forward-Looking Statements for
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding expectations for a new services business and a collaboration agreement. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to the potential adverse effects of the coronavirus pandemic on our business and operating results during 2020; risks relating to company research and development and distribution plans and capabilities; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting
Vice President, Investor Relations
650 416 7423
Senior Director, Corporate Communications
650 243 6621
Source: Fluidigm Corporation